<DOC>
	<DOCNO>NCT01264705</DOCNO>
	<brief_summary>This non-randomized , open-label , single-institution phase I/II therapeutic trial bavituximab sorafenib patient advance hepatocellular carcinoma ( HCC ) . This study activate UT Southwestern Medical Center , comprise The Harold C. Simmons Comprehensive Cancer Center , UT Southwestern Hospitals-St. Paul Parkland Memorial Hospital System . Advanced HCC define disease amenable surgical resection orthotopic liver transplantation metastatic nature .</brief_summary>
	<brief_title>Study Bavituximab Sorafenib In Patients With Advanced Liver Cancer</brief_title>
	<detailed_description>The investigator look men woman age 18 year old hepatocellular carcinoma suitable surgical resection hepatic transplantation . Prior locoregional therapy include limited transarterial chemoembolization ( TACE ) , radiofrequency ablation ( RFA ) ethanol injection allow long treatment 4 week previous . Patients must Child-Pugh A previous treatment sorafenib vascular endothelial growth factor ( VEGF ) inhibitor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must diagnosis hepatocellular carcinoma least one criterion list : Histologically confirm . MRI CT consistent liver cirrhosis least one solid liver lesion &gt; 2 cm early enhancement delay enhancement washout regardless AFP . AFP &gt; 400 ng/ml evidence least one solid liver lesion &gt; 2 cm regardless specific image characteristic CT MRI . 2 . Locally advanced metastatic disease . 3 . Patients locally advanced disease must disease deem unresectable eligible hepatic transplantation . Determination occur weekly GI DMT meeting surgical oncologist transplant surgeon . 4 . Measurable disease , define lesion accurately measure least one dimension ( long diameter measure ) accord Response Evaluation Criteria Solid Tumors ( RECIST , version 1.1 ) least 2 cm conventional technique least 1 cm spiral compute tomography . 5 . ChildPugh Score A . 6 . Age ≥ 18 year . 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 . 8 . Absolute neutrophil count ≥ 1,500 cells/mm3 . 9 . Platelet count ≥ 75,000 cells/mm3 . 10 . Total bilirubin ≤ 3.0 mg/dl . 11 . Hemoglobin ≥ 8.5 g/dl . 12 . AST ALT ≤ 5.0 time upper limit normal . 13 . Ddimer ≤ 3 time upper limit normal . 14 . INR ≤ 1.8 ( therapeutic anticoagulation allow long medically indicate . 1 . History bleed diathesis coagulopathy . 2 . Symptomatic clinically active brain metastasis . 3 . Major surgery within previous 4 week . 4 . History thromboembolic event ( include pulmonary embolism deep vein thrombosis ) ; central venous catheterrelated thrombosis &gt; 6 month prior allow . 5 . Prior adjuvant therapy sorafenib Raf/MEK/RAS VEGFR inhibitor . Prior adjuvant therapy allow provide complete &gt; 6 month ago document recurrence hepatocellular carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>GI Cancer</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Oncology</keyword>
</DOC>